Efficiencies of Four Versions of the AMPLICOR HIV-1 MONITOR Test for Quantification of Different Subtypes of Human Immunodeficiency Virus Type 1
Efficiencies of Four Versions of the AMPLICOR HIV-1 MONITOR Test for Quantification of Different Subtypes of Human Immunodeficiency Virus Type 1
复制标题
四种版本的 AMPLICOR HIV-1 MONITOR 测试对 1 型人类免疫缺陷病毒不同亚型进行定量的效率
DOI：
--
复制
发表时间：
1999
影响因子：
9.4
通讯作者：
M. Peeters
中科院分区：
文献类型：
--
作者：
K. Triques;J. Coste;J. Perret;C. Segarra;E. Mpoudi;J. Reynes;E. Delaporte;A. Butcher;Kimberly Dreyer;S. Herman;J. Spadoro;M. Peeters
商业人类免疫缺陷病毒（HIV）1型（HIV-1）载量检测的三个版本（AMPLITOR COR HIV-1 MONITOR Test版本1.0、1.0+和1.5; Roche Diagnostics，Branchburg，NJ）评估了它们检测和定量不同基因亚型的HIV-1 RNA的能力。96例不同亚型HIV-1感染者的血浆样本（55例感染A亚型、9例感染B亚型、21例感染C亚型、2例感染D亚型、7例感染E亚型和2例感染G亚型的患者）和来自29株HIV-1参考毒株的培养病毒A亚型3例，B亚型B 6例，C亚型5例，D亚型3例，E亚型8例，F亚型3例，G亚型1例。与版本1.0相比，版本1.0+和1.5显著改善了亚型A和E的检测，而亚型B、C、D和G的检测与三个版本相当。版本1.0、1.0+和1.5分别检测到65%、98%和100%的A亚型感染患者样本，以及71%、100%和100%的E亚型感染患者样本。版本1.5使A和E亚型感染样本的病毒载量显著增加（大于1 log 10 HIV RNA拷贝/ml）。对于感染亚型B、C和D并使用版本1.5检测的样本，仅观察到病毒载量轻微增加（<0.5 log 10）。我们还评估了使用与版本1.5相同的PCR引物的测试的原型自动化版本。对于所有亚型，原型自动化测试的结果与1.5版测试的结果高度相关，但总体上较低。AMPENTAL COR HIV-1 MONITOR Test 1.5版可准确测量所有HIV-1亚型的HIV载量，因此可用于评估M组HIV-1亚型感染患者的疾病预后和抗逆转录病毒治疗反应。
ABSTRACT Three versions of a commercial human immunodeficiency virus (HIV) type 1 (HIV-1) load test (the AMPLICOR HIV-1 MONITOR Test versions 1.0, 1.0+, and 1.5; Roche Diagnostics, Branchburg, N.J.) were evaluated for their ability to detect and quantify HIV-1 RNA of different genetic subtypes. Plasma samples from 96 patients infected with various subtypes of HIV-1 (55 patients infected with subtype A, 9 with subtype B, 21 with subtype C, 2 with subtype D, 7 with subtype E, and 2 with subtype G) and cultured virus from 29 HIV-1 reference strains (3 of subtype A, 6 of subtype B, 5 of subtype C, 3 of subtype D, 8 of subtype E, 3 of subtype F, and 1 of subtype G) were tested. Detection of subtypes A and E was significantly improved with versions 1.0+ and 1.5 compared to that with version 1.0, whereas detection of subtypes B, C, D, and G was equivalent with the three versions. Versions 1.0, 1.0+, and 1.5 detected 65, 98, and 100% of the subtype A-infected samples from patients, respectively, and 71, 100, and 100% of the subtype E-infected samples from patients, respectively. Version 1.5 yielded a significant increase in viral load for samples infected with subtypes A and E (greater than 1 log10 HIV RNA copies/ml). For samples infected with subtype B, C, and D and tested with version 1.5, only a slight increase in viral load was observed (<0.5 log10). We also evaluated a prototype automated version of the test that uses the same PCR primers as version 1.5. The results with the prototype automated test were highly correlated with those of the version 1.5 test for all subtypes, but were lower overall. The AMPLICOR HIV-1 MONITOR Test, version 1.5, yielded accurate measurement of the HIV load for all HIV-1 subtypes tested, which should allow the test to be used to assess disease prognosis and response to antiretroviral treatment in patients infected with a group M HIV-1 subtype.